Browse the evidence

Reduced lumbar lordosis angle is a significant independent factor for paraspinal muscle atrophy in preoperative lumbar spinal stenosis and lumbar disk herniation patients.

Practitioners should consider lumbar lordosis angle when assessing risk for muscle atrophy in these patients.

Seven French raw-milk cheeses showed biological activities in vivo and in vitro.

Cheeses may be considered functional foods with potential health benefits.

Fractions (polar and apolar) reduced inflammatory markers in human chondrocytes.

Cheese fractions may have potential anti-inflammatory effects on joint health.

GLP-1-based therapies can lead to significant aesthetic issues in the face and neck, including midface volume loss and increased skin laxity.

Practitioners should be aware of these aesthetic concerns when treating patients on GLP-1 therapies.

Multimodal nonsurgical aesthetic treatments are recommended for addressing aesthetic issues in GLP-1 weight loss patients.

Practitioners should consider a combination of treatments for optimal aesthetic outcomes.

MitoQ supplementation reduced mitochondrial H2O2 emission capacity in skeletal muscle.

MitoQ may reduce oxidative stress in skeletal muscle for older adults.

Individuals with type 2 diabetes have significantly higher levels of inflammatory markers compared to an unaffected population.

Practitioners should consider monitoring inflammatory markers in patients with type 2 diabetes.

There is a significant positive association between C-reactive protein (CRP) levels and body mass index (BMI) in individuals with type 2 diabetes.

Monitoring BMI may provide insights into inflammation levels in diabetic patients.

Metformin failed to prove beneficial effects in MASLD progression.

Avoid using metformin for treating MASLD progression as it has not shown benefits.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.

No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.

Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.

Both drugs are associated with kidney and thyroid disorders.

Healthcare providers should monitor kidney and thyroid function in patients using these medications.

Systematic screening for advanced fibrosis related to MASLD is recommended for patients with T2D.

Healthcare professionals should implement systematic screening for liver fibrosis in diabetic patients.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.

Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.

Clinicians should monitor for gastrointestinal side effects in patients taking semaglutide.

The translational application of browning agents in humans faces challenges.

Practitioners should be aware of the limitations when considering browning agents for treatment.

People with MASH and clinically significant fibrosis are at risk of progressing to cirrhosis and hepatocellular carcinoma.

Monitoring and intervention are crucial for patients with MASH and fibrosis.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the population.

Health practitioners should be aware of the high prevalence of MASLD in their patient populations.

There is an urgent need for fundamental research to understand the mechanisms of metabolic disorders and cardiovascular disease.

Invest in research to better understand and treat metabolic and cardiovascular diseases.

Collagen and free amino acid ingestion did not significantly increase myofibrillar protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance muscle protein synthesis in healthy individuals post-exercise.

Collagen and free amino acid ingestion did not significantly increase muscle connective protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance connective tissue protein synthesis in healthy individuals post-exercise.

Rifampicin enhances lipolysis and suppresses lipogenesis in adipocytes.

Rifampicin may be useful in promoting fat loss by altering lipid metabolism.